Koshkin, V. S., Sun, Y., Osterman, C. K., Natesan, D., Su, C., Lemke, E., … Alva, A. (2020). 771P Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer. In Annals of Oncology (Vol. 31, pp. S594–S594). Elsevier BV. https://doi.org/10.1016/j.annonc.2020.08.843

Koshkin, V. S., Y. Sun, C. K. Osterman, D. Natesan, C. Su, E. Lemke, A. R. Khaki, et al. “771P Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer.” In Annals of Oncology, 31:S594–S594. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.843.

Koshkin VS, Sun Y, Osterman CK, Natesan D, Su C, Lemke E, et al. 771P Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer. In: Annals of Oncology. Elsevier BV; 2020. p. S594–S594.

Koshkin, V. S., et al. “771P Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer.” Annals of Oncology, vol. 31, Elsevier BV, 2020, pp. S594–S594. Crossref, doi:10.1016/j.annonc.2020.08.843.

Koshkin VS, Sun Y, Osterman CK, Natesan D, Su C, Lemke E, Khaki AR, Johnson A, Owens X, Park JJ, Basu A, Coelho Barata PM, Davis N, Grivas P, Milowsky M, Kilari D, Alva A. 771P Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer. Annals of Oncology. Elsevier BV; 2020. p. S594–S594.